Seattle Genetic has plans to expand the use of its first cancer drug. The company plans to widen its shelf of drugs with multiple new drugs set for cancer treatment. The Bothell-based company is also set to increase its number of employees. Advancements made by the company is to enable it achieve its vision.
According to the company Chief Executive Officer, Dr. Clay Siegall, Seattle Genetics has tried its first Adcetris drug in several situations. There have been up to 70 different trials of the drug on multiple cancer cells. Results from the drug show that it is going to be used to fight lymphomas. The company has made a huge revenue from selling the drug. It made $226 million in terms of revenue the previous year. Seattle Genetics has partnered with several pharmaceuticals, this has seen the drug being sold to several parts of the world especially in Canada and the US.
With the new plan to introduce more drugs in the market, Adcetris is going to be another drug produced by the company. Seattle Genetics is currently working to release 12 more drugs. One of the drugs currently has the label 33A. It will be through with clinical trials before the end of 2016. The drug is going to be highly resourceful in the treatment of leukemia. The company has also ventured into other drugs that focus on treatment of bladder cancer and breast cancer. Seattle Genetics today has approximately 800 employees. It has plans to expand by acquiring an additional 100 employees.
Dr. Clay Siegall co-founded Seattle Genetics, he has worked under the company for many years now. He served as the Interim Chairman since April 2004. He has been the director of the company since it was started in 2007. Clay has had a keen interest to help cancer patients. This has seen him work with several national research and treatment institutions that focus on treatment of cancer. He has received multiple awards for his efforts. His success is highly attributed to his educational background. He has a Ph.D. in Genetics and a B.S. in Zoology.